1Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC.
2Comparative Medicine Institute, North Carolina State University, Raleigh, NC.
J Am Vet Med Assoc. 2023 Aug 29;261(10):1435-1442. doi: 10.2460/javma.23.07.0388. Print 2023 Oct 1.
The purpose of this manuscript, which is part of the Currents in One Health series, is to take a comparative approach to stem cell treatment for tendon injury and consider how the horse might inform treatment in other veterinary species and humans. There is increasing experimental and clinical evidence for the use of bone marrow-derived mesenchymal stem cells to treat tendon injuries in the horse. The same evidence does not currently exist for other species. This manuscript will review why the equine superficial digital flexor tendon core lesion might be considered optimal for stem cell delivery and stem cell interaction with the injury environment and will also introduce the concept of stem cell licensing for future evaluation. The companion Currents in One Health by Koch and Schnabel, AJVR, October 2023, addresses in detail what is known about stem cell licensing for the treatment of other diseases using rodent models and how this information can potentially be applied to tendon healing.
本文是 One Health 系列的一部分,旨在采用对比的方法来研究干细胞治疗肌腱损伤,并探讨马对其他兽医物种和人类治疗的启示。越来越多的实验和临床证据表明,骨髓间充质干细胞可用于治疗马的肌腱损伤。但目前在其他物种中还没有同样的证据。本文将讨论为什么马的趾浅屈肌腱核心病变被认为是干细胞输送的最佳选择,以及干细胞与损伤环境的相互作用,并将介绍干细胞许可的概念,以供未来评估。Koch 和 Schnabel 在同一期的 One Health 中详细介绍了使用啮齿动物模型治疗其他疾病的干细胞许可,以及如何将这些信息应用于肌腱愈合。